Explore some selected publications from Dr. Ehret below.

Original Research

Ehret MJ, Sobieraj D.   Prevention of Interferon-Alpha Associated Depression with Antidepressant Medications in Patients with Hepatitis C Virus: A Systematic Review and Meta-Analysis. International Journal of Clinical Practice 2014;68(2):255-61. 

Ehret MJ, Baker WL, O’Neill H. BDNF Val66Met Polymorphism and Lithium Response: A Meta-Analysis. Personalized Medicine 2013;10(8):777-784. 

Ehret MJ, Shelton D, Barta W, Trestman R, Maruca A, Kamath J, Golay L. Medication Adherence Among Female Inmates with Bipolar Disorder: Results From a Randomized Controlled Trial. Psychol Serv 2013;10:106-14. 

Shelton D, Ehret MJ, Wakai S, Kapetanovic T, Moron M. Psychotropic medication adherence in correctional facilities: a review of the literature. Journal of Psychiatric and Mental Health Nursing 2010;17:603-13. 

Ehret MJ, Goethe J, Lanosa M, Coleman CI. The Effect of Metformin on Anthropometrics and Insulin Resistance in Patients Receiving Atypical Anti-Psychotic Agents. J Clin Psych 2010;71:1286-92.

Ehret MJ, Levin GM, Narasimhan M, Rathinavelu A. Venlafaxine induces p-glycoprotein in human Caco-2 cells. Hum Psychopharmacol Clin Exp 2007;22:49-53.

Levin GM, Bowles TA, Ehret MJ, et al. Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol Diag Ther 2007;11(3):155-60.

Book Chapters

Ehret MJ, Caley CF.  Bipolar Disorder.  Applied Therapeutics.  In press.

Ehret MJ.  Medication Therapy Management for Bipolar Disorder.  McGraw Hill, in press.

Gugger JJ, Ehret MJ. Orthostatic Hypotension. Life Threatening Effects of Antipsychotic Drugs. Ed. Maun, Flanagan, Ronaldson. In press.

Ehret MJ.  Bipolar Disorder.  ACSAP.  May 2017.

Ehret MJ. Central Nervous System. Concepts in Pharmacogenomics. Ed. Zdanowicz MM. American Society of Health System Pharmacists, 2016.

Ehret MJ, Chamberlin K. Alzheimer’s Disease. Pharmacotherapy Principles and Practice. Fourth Edition. Ed. Chisholm, Schwinghammer, Wells, DiPiro, Kolesar, and Malone. New York, New York: McGraw-Hill, 2016.

Ehret MJ.   Medication Therapy Management for Bipolar Disorder. Access Pharmacy, 2014.

Ehret MJ. Alzheimer’s Disease. Pharmacotherapy Principles and Practice Study Guide. Ed. Katz, Matthias, Chisholm-Burns. New York, New York: McGraw-Hill, 2013.

Ehret MJ, Clayton E. Alzheimer’s Disease. Pharmacotherapy Principles and Practice. Third Edition. Ed. Chisholm, Schwinghammer, Wells, DiPiro, Kolesar, and Malone. New York, New York: McGraw-Hill, 2013.

Ehret MJ. Rating Scales in Psychiatric Disorders. PSAP 7th edition, Book 10. April 2012.

Ehret MJ. Alzheimer’s Disease. Pharmacotherapy Principles and Practice Study Guide. Ed. Katz, Matthias, Chisholm-Burns. New York, New York: McGraw-Hill, 2011.

Ehret MJ. Central Nervous System. Concepts in Pharmacogenomics. Ed. Zdanowicz MM. American Society of Health System Pharmacists, 2010.

Ehret MJ, Levin GM, Bowles TM. Alzheimer’s Disease. Pharmacotheray Principles and Practice. Second Edition. Ed. Chisholm, Schwinghammer, Wells, DiPiro, Kolesar, and Malone. New York, New York: McGraw-Hill, 2010.

Levin GM, Bowles TM, Ehret MJ. Alzheimer’s Disease. Pharmacotherapy Essentials. Ed.Chisholm, Schwinghammer, Wells, DiPiro, Kolesar, and Malone. New York, New York: McGraw-Hill, 2005.

Review Articles

Choi E, Zmarlicka M, Ehret MJ. Vilazodone: A Novel Antidepressant. Am J Health Syst Pharm 2012;15:1551-7.
Ehret MJ, Wang M. How to Increase Medication Adherence: What Works? Ment Health Clin 2013;2:11.

Ehret MJ. The Basics of Pharmacogenomics. Mental Health Clinician. March 2012.

Ehret MJ. The Effect of Metformin on Anthropometrics and Insulin Resistance in Patients Receiving Atypical Antipsychotic Agents-Reprise. Mental Health Clinician. July 2011.

Ehret MJ. Book Review- Principles of the Human Genome and Pharmacogenomics. Annals of Pharmacotherapy; e-pub ahead of print: DOI 10.1345/aph.1Q116. June 2011.

Delgado A, Ehret MJ. Atypical Antipsychotic Augmentation in Treatment-Resistant Major Depressive Disorder. Conn Med 2011;75:153-6.

Ehret MJ, Sopko MS, Lemieux T. Focus on lurasidone: a new atypical antipsychotic for the treatment of schizophrenia. Formulary 2010;45:313-17.

Ehret MJ. Pharmacological treatment of bipolar depression. Conn Med 2010;74:407-11.

Chavez B, Sopko MA, Ehret MJ, et al. An Update on CNS Stimulant Formulations in Children and Adolescents with Attention-Deficit Hyperactivity Disorder. Annals of Pharmacotherapy 2009;43:1084-95.

Grgas M, Ehret MJ.   Psychopharmacology: Much the Same. Conn Medicine 2009;73:281-4.

Sopko MA, Ehret MJ, Grgas M. Desvenlafaxine: Another “Me Too” Drug? Annals of Pharmacotherapy 2008;42:1439-46.

Ehret MJ, Sopko MA, Levine A. Iloperidone: a novel atypical antipsychotic for the treatment of schizophrenia. Formulary 2008;43:190-203.

Ehret MJ, Chavez B. A review of the STAR*D trial. Journal of Pharmacy Practice 2006;19:353-60.

Ehret MJ. Pharmacogenomics of antidepressant medications. Journal of Pharmacy Practice 2006;19:342-52.

Luque CA, Ehret MJ, Rey JA. Rimonabant (Acomplia): the first cannabinoid-1 receptor blocker fr obesity. P&T 2007;32(4):209-213.

Ehret MJ, Levin GM. The long-term use of atypical antipsychotics in bipolar disorder. Pharmacotherapy 2006;26(8):1134-47.

Ehret M, Fuller M. Long-Acting injectable risperidone. Annals of Pharmacotherapy 2004;28(12):2122-27.

Presentations 

“Long Acting Injectable Antipsychotics”
IPS-APA Meeting
New Orleans, LA; October 2017

“Burden of Medical Co-Morbidity in Men and Women with Serious Mental Illness”
American Association of Public Health Annual Meeting
Boston, MA; November 2013

“Medication Adherence in a Corrections Population with Bipolar Disorder”
National Commission on Correctional Health Care Annual Meeting-Only Pharmacist presenting at meeting
Las Vegas, NV; July 2013

“Metabolic Syndrome in a Corrections Population Treated with Antipsychotics”
Academic and Health Policy Conference on Correctional Health
Chicago, IL; March 2013

“Is Antidepressant Use in Bipolar Disorder Associated with Higher Remission Rates?
American Psychiatric Association Annual Meeting- One of five pharmacists presenting at meeting
Philadelphia, PA; May 2012

 Current Prescribing Practices: Antidepressant Use in Schizophrenia”
College of Psychiatric and Neurologic Pharmacists Annual Meeting
Tampa, Florida; April 2012

 “Psychotropic Medication Adherence: Development of an Inmate Interview Process”
College of Psychiatric and Neurologic Pharmacists Annual Meeting
Phoenix, Arizona; May 2011

“Expectancy Therapy for Smoking Cessation”
American Psychiatric Association Meeting
Honolulu, Hawaii; May 2011

“Current Prescribing Practices: Antidepressant Use in Schizophrenia”
American Psychiatric Association Meeting
Honolulu, Hawaii; May 2011

“Medication Adherence in a Corrections Population with Bipolar Disorder”
4th Academic and Health Policy Conference on Correctional Health
Boston, MA; May 2011

“Prescribing Patterns in a Corrections Population with Bipolar Disorder”
4th Academic and Health Policy Conference on Correctional Health
Boston, MA; May 2011

“The Effect of Psychotropic Medication Dosing on Symptom Control for Inmates Diagnosed with Bipolar Disorder”
New Investigator Award/Poster Presentation at the College of Psychiatric and Neurologic Pharmacists Annual Meeting
San Antonia, TX; April 2010

“Who Receives Guideline-based Pharmacotherapy for Bipolar Depression?”
Platform Presentation at American Psychiatric Association
San Francisco, CA; May 2009

“An Analysis of CYP450 Genotype and Patients’ Perceived Response and Tolerance to Their Antidepressants”
College of Psychiatric and Neurologic Pharmacists Meeting
Jacksonville, Florida; April 2009

“Determining the Mechanism of a Drug-Drug Interaction: Venlafaxine and P-glycoprotein”
2006 NCDEU New Investigator Award; June 2006